On Tuesday, Avadel Pharmaceuticals plc (NASDAQ: AVDL) was 5.12% up from the session before settling in for the closing price of $7.61. A 52-week range for AVDL has been $7.39 – $19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 68.50% over the last five years. When this article was written, the company’s average yearly earnings per share was at 125.29%. With a float of $88.35 million, this company’s outstanding shares have now reached $96.52 million.
The firm has a total of 188 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.97%, operating margin of -25.07%, and the pretax margin is -29.02%.
Avadel Pharmaceuticals plc (AVDL) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Avadel Pharmaceuticals plc stocks. The insider ownership of Avadel Pharmaceuticals plc is 8.57%, while institutional ownership is 79.77%. The most recent insider transaction that took place on Jan 21 ’25, was worth 39,640. In this transaction Director of this company bought 5,000 shares at a rate of $7.93, taking the stock ownership to the 67,900 shares. Before that another transaction happened on Jan 13 ’25, when Company’s Director bought 10,000 for $8.04, making the entire transaction worth $80,450. This insider now owns 104,055 shares in total.
Avadel Pharmaceuticals plc (AVDL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 125.29% per share during the next fiscal year.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
You can see what Avadel Pharmaceuticals plc (AVDL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach 0.65 in one year’s time.
Technical Analysis of Avadel Pharmaceuticals plc (AVDL)
Analysing the last 5-days average volume posted by the [Avadel Pharmaceuticals plc, AVDL], we can find that recorded value of 1.04 million was lower than the volume posted last year of 1.59 million. As of the previous 9 days, the stock’s Stochastic %D was 44.49%. Additionally, its Average True Range was 0.43.
During the past 100 days, Avadel Pharmaceuticals plc’s (AVDL) raw stochastic average was set at 6.58%, which indicates a significant decrease from 40.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.07% in the past 14 days, which was lower than the 82.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.55, while its 200-day Moving Average is $12.67. Now, the first resistance to watch is $8.16. This is followed by the second major resistance level at $8.32. The third major resistance level sits at $8.63. If the price goes on to break the first support level at $7.69, it is likely to go to the next support level at $7.38. Now, if the price goes above the second support level, the third support stands at $7.22.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Key Stats
There are 96,629K outstanding shares of the company, which has a market capitalization of 773.04 million. As of now, sales total 169,120 K while income totals -48,830 K. Its latest quarter income was 50,410 K while its last quarter net income were -5,040 K.
